GlassScriptPhysician profile
Naresh J Solanki
NPI 1225007412
$6,458.26
in general payments reported to CMS, 2019-2025
31 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 97% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $399 · 2021: $604 · 2022: $915 · 2023: $1,044 · 2024: $1,135 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,020.07 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $919.41 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $821.88 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $706.96 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Glaxosmithkline, LLC. | $513.71 | 2019-2025 | Penmenvy, Bexsero, Shingrix |
| Collegium Pharmaceutical, INC. | $284.32 | 2025 | Jornay Pm |
| Kaleo, INC. | $216.92 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $191.71 | 2022-2025 | Doc Band |
| Sanofi Pasteur INC. | $173.32 | 2019-2025 | |
| Neos Therapeutics, LP | $170.70 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Merck Sharp & Dohme LLC | $157.38 | 2019-2024 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Ars Pharmaceuticals Operations, INC. | $147.98 | 2025 | Neffy |
| Rhodes Pharmaceuticals L.P. | $138.86 | 2019 | |
| Emd Serono, INC. | $106.02 | 2019 | |
| Seqirus USA INC | $105.76 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $100.91 | 2024 | Xelstrym |
| Noven Therapeutics, LLC | $90.32 | 2024 | Xelstrym |
| Shire North American Group INC | $81.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.98 | 2020-2021 | |
| Sobi, INC | $78.66 | 2022-2023 | |
| Adlon Therapeutics L.P. | $66.38 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $65.42 | 2023-2024 | Flumist Quadrivalent |
| Vertical Pharmaceuticals, LLC | $56.60 | 2019-2025 | Relexxii |
| Pfizer INC. | $34.04 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $32.61 | 2025 | |
| Biomarin Pharmaceutical INC. | $24.92 | 2022 | |
| Alk-Abello, INC | $22.81 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $19.92 | 2023 | |
| Teleflex LLC | $16.92 | 2023 | Trapliner |
| Arbor Pharmaceuticals, INC. | $11.67 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Solanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.